Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Clinical trial NCT02083354 · COMPLETED
Trial details
- NCT number
- NCT02083354
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-18
- Primary completion
- 2018-02-23
- Enrollment
- 77
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.